bpc157 + tb500 + ghk-cu blend Glow (BPC-157/TB-500/GHK-Cu) — IVs in the Keys GLOW | GHK-Cu / TB-500

Ta1 activates both myeloid and plasmacytoid dendritic cells through these receptors, initiating signaling pathways that lead to appropriate (not excessive) immune activation

By strategically combining the GHK-Cu GLOW stack with other therapies, you can create a synergistic effect where each treatment supports and amplifies the others

Obviously, the effects of one growth factor could be not unified when obtained with addition (and help) of different carriers (Seiwerth et al., 2018), and regardless given highly sophisticated evidence (Tarnawski and Ahluwalia, 2012

At these high doses, a small but consistent percentage of B12 is absorbed by passive diffusion, bypassing the intrinsic factor mechanism

Risks / Unknowns: FDA "Category 2" status (2023) limits compounding

lumbar or sacral, single level